TOP TEN perturbations for NM_000039 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000039
Selected probe(set): 204450_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000039 (204450_x_at) across 5339 perturbations tested by GENEVESTIGATOR:

hepatocyte-like cell differentiation study 1 (15d) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):7.3169107
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

hepatocyte-like cell differentiation study 1 (10d) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):6.5614786
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (10d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to hepatic specification stage for 10 days.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (15d)

Relative Expression (log2-ratio):-5.416934
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.

stem cell differentiation study 41 (hES-T3 EB) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):5.326088
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

MSHRIe002-A-SOX17 / MSHRIe002-A-con

Relative Expression (log2-ratio):4.9342327
Number of Samples:4 / 2
Experimental MSHRIe002-A-SOX17
Human embryonic stem cells overexpressing SOX17. Cells were generated by two stable transfections. Firstly, cells were transfected with the Cre-inducible expression vector for SOX7. In the second step, electroporation with a CRE recombinase vector (pCAGGS-NLS-CRE) and selection with puromycin was performed. Parental cell line:: MSHRIe002-A Synonyms:SOX17 O/E HESC
Control MSHRIe002-A-con
Human embryonic stem cells MSHRIe002-A modified by stable control transfection. Parental cell line:: MSHRIe002-A, CA2

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (10d)

Relative Expression (log2-ratio):-4.661502
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (10d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to hepatic specification stage for 10 days.

celiac disease study 1 (gluten-free) / celiac disease study 1 (active)

Relative Expression (log2-ratio):4.2956953
Number of Samples:9 / 9
Experimental celiac disease study 1 (gluten-free)
Duodenum tissues derived from patients with celiac disease treated for 2 years with gluten-free diet.
Control celiac disease study 1 (active)
Duodenum tissues derived from patients with active celiac disease. Biopsies were taken at the time of diagnosis.

ovarian tumor study 28 (clear cell adenocarcinoma) / ovarian tumor study 28 (adenocarcinoma)

Relative Expression (log2-ratio):-4.221154
Number of Samples:6 / 3
Experimental ovarian tumor study 28 (clear cell adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma.
Control ovarian tumor study 28 (adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with adenocarcinoma.

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):-4.001978
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

HCC study 3 (area A) / HCC study 3 (area C)

Relative Expression (log2-ratio):-3.9555597
Number of Samples:13 / 24
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area C)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.